DPP4 and Hyperglycemia: For example, in the treatment of hyperglycaemia, glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) have been shown to reduce cardiovascular events and mortality, while dipeptidyl peptidase 4 (DPP4) inhibitors have not shown the same benefits [12, 13].